NCT03941405

Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)

Albumin for Management of Hypervolemic Hyponatremia in Patients With Decompensated Cirrhosis. A Proof of Concept Study.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Fundacion Clinic per a la Recerca Biomédica · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period

Conditions

• Hyponatremia With Excess Extracellular Fluid Volume
• Cirrhosis, Liver

Interventions

Type	Name	Description
DRUG	Albumin treatment	one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period

Timeline

• Start date: 2020-02-01
• Primary completion: 2024-12-28
• Completion: 2025-01-30
• First posted: 2019-05-08
• Last updated: 2025-02-28

Locations

3 sites across 1 country: Spain